Cite
Martín I, Villamón E, Abellán R, et al. Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations. Br J Haematol. 2021;194(4):708-717doi: 10.1111/bjh.17675.
Martín, I., Villamón, E., Abellán, R., Calasanz, M. J., Irigoyen, A., Sanz, G., Such, E., Mora, E., Gutiérrez, M., Collado, R., García-Serra, R., Vara, M., Blanco, M. L., Oiartzabal, I., Álvarez, S., Bernal, T., Granada, I., Xicoy, B., Jerez, A., Calabuig, M., Diez, R., Gil, �. �., Díez-Campelo, M., Solano, C., Tormo, M. (2021). Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations. British journal of haematology, 194(4), 708-717. https://doi.org/10.1111/bjh.17675
Martín, Iván, et al. "Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations." British journal of haematology vol. 194,4 (2021): 708-717. doi: https://doi.org/10.1111/bjh.17675
Martín I, Villamón E, Abellán R, Calasanz MJ, Irigoyen A, Sanz G, Such E, Mora E, Gutiérrez M, Collado R, García-Serra R, Vara M, Blanco ML, Oiartzabal I, Álvarez S, Bernal T, Granada I, Xicoy B, Jerez A, Calabuig M, Diez R, Gil Á, Díez-Campelo M, Solano C, Tormo M. Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations. Br J Haematol. 2021 Aug;194(4):708-717. doi: 10.1111/bjh.17675. Epub 2021 Jul 22. PMID: 34296432.
Copy
Download .nbib